Cardiocore Selected as Preferred Provider
Cardiocore, a centralized cardiac testing lab, announced its preferred provider status with a top 10 pharmaceutical company. Cardiocore was awarded cardiac safety service contracts in multi-year studies including a Thorough QT study and retrospective paper ECG analyses.
This is the company's second such announcement in the past three months. It had previously announced it was selected by an unnamed top 10 biotech.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
